Skip to content
OpenCapital
Get started

Kairos Pharma KAPA Q3 2025 earnings

Reported November 14, 2025 · Before market open

Diluted EPS-$0.07Beat by $0.03
EPS estimate-$0.10

Next report

Aug 11, 2026 (In 4 weeks)
EPS estimate-$0.09

Versus estimates

Diluted EPS

Q1 2026-$0.08Miss by $0.01Q4 2025-$0.07Miss by $0.05
Q3 2025-$0.07Beat by $0.03
Q2 2025-$0.08Miss by $0.02Q1 2025-$0.08Miss by $0.03Q4 2024-$0.09Miss by $0.03

Ask the moment Kairos Pharma reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Kairos Pharma report Q3 2025 earnings?
Kairos Pharma (KAPA) reported Q3 2025 earnings on November 14, 2025 before market open.
What were Kairos Pharma's Q3 2025 revenue and EPS?
Kairos Pharma reported diluted EPS of $-0.07 for Q3 2025.
Did Kairos Pharma beat estimates in Q3 2025?
EPS beat the consensus estimate of $-0.10 by $0.03.
How did Kairos Pharma's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 30.0% from $-0.10.
Where can I find Kairos Pharma's Q3 2025 SEC filings?
You can read the 10-Q periodic report (0001493152-25-023276) directly on SEC EDGAR. The filing index links above go to sec.gov.